AOD-9604 reconstitution and dosage: hypothetical concentration and U-100 conversions, formulation-specific stability, oral trial history, and injection gaps.
AOD-9604 reconstitution and human dosage are separate questions. A validated research procedure must establish diluent compatibility and stability; concentration arithmetic does not establish a daily injection amount. No FDA-approved AOD-9604 human drug product exists.
What AOD-9604 Is and Why Mixing Matters
AOD-9604 contains hGH residues 177-191 with an additional N-terminal tyrosine, making a modified 16-amino-acid peptide. The common name HGH fragment 176-191 should not be read as an unchanged native sequence.
How you mix the vial decides how accurately you can measure a dose. Get the concentration wrong and the same syringe reading can deliver double or half the intended amount.
The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations. The company terminated obesity development in 2007; this should not be described as an FDA rejection in that year. The 2026 WADA list places AOD-9604 in S2.2.3 among growth-hormone fragments, not S0.
How to Reconstitute AOD-9604 Step by Step
A vial's mass does not determine the correct diluent or final volume. Bacteriostatic water is not automatically compatible, and its preservative does not sterilize a contaminated preparation.
- Identify material form and batch.
- Use a compatible diluent and a validated target concentration.
- Follow specified mixing and clean-handling conditions.
- Record final volume and preparation details.
- Check formulation-specific quality and stability requirements.
If the Powder Will Not Fully Dissolve
Do not add another volume of liquid or warm a cloudy sample as an improvised rescue. Appearance cannot establish whether the problem is solubility, aggregation, degradation, or contamination.
The Reconstitution Math: Concentration and Syringe Units
Concentration equals peptide mass divided by final solution volume. The table assumes those final volumes and uses 300 mcg as a hypothetical laboratory aliquot, not a human dose or a validated preparation recipe.
| Sample mass | Assumed final volume | Calculated concentration | 300 mcg laboratory aliquot (U-100 units) |
|---|---|---|---|
| 5 mg | 1 mL | 5000 mcg/mL | 6 |
| 5 mg | 2 mL | 2500 mcg/mL | 12 |
| 5 mg | 3 mL | Approximately 1667 mcg/mL | 18 |
| 2 mg | 1 mL | 2000 mcg/mL | 15 |
| 2 mg | 2 mL | 1000 mcg/mL | 30 |
For aod-9604 5mg dosage arithmetic, the same hypothetical aliquot occupies different volumes at different concentrations. Measurement convenience does not establish that a more dilute formulation is compatible or stable.
What Does the Human Dose Evidence Establish?
The human record reviewed in 2024 did not establish a subcutaneous dose-response relationship. Community amounts are not a validated injection protocol.
| Claim | Evidence needed | Reviewed limitation |
|---|---|---|
| Conservative starting amount | Human subcutaneous dose-finding and tolerability | Not established |
| Standard daily amount | Reproducible dose-response data | Not established |
| Higher or split amount | Exposure, outcome, and safety comparison | Not established |
An aod 9604 dosage protocol needs more than a known concentration. Concentration converts a specified amount to volume; it cannot identify an effective human amount.
Timing and Frequency
The review did not establish a human subcutaneous half-life, fasting interval, or clinical advantage to morning or pre-meal administration. Site rotation is a procedural issue, not evidence validating AOD-9604 use.
Men, Women, and Beginners
An aod 9604 dosage for men guide cannot establish sex- or weight-based amounts by repeating community ranges. The reviewed evidence did not establish a male- or female-specific human injection regimen.
An aod 9604 peptide dosage for beginners cannot be called reasonable or conservative without dose-finding and safety evidence. Tolerating an anecdotal amount does not validate an escalation plan.
Some users combine AOD-9604 with other research compounds, but those pairings have not been tested for safety or effectiveness in humans and should be treated as experimental.
Storage and Stability After Reconstitution
- Use storage and beyond-use information supported for the specific form and formulation.
- Record final concentration and any required storage conditions.
- Do not assume a universal refrigerator, freezer, or two-to-four-week rule.
- Do not use a cloudy, gelled, or otherwise abnormal sample.
Safety, Legality, and Side Effects
No FDA-approved AOD-9604 human drug product exists. A research-use listing does not establish lawful human treatment; the relevant product and practice requirements are not a blanket purchasing or possession rule.
The reviewed human safety information concerned oral and intravenous administration. It does not establish a generally mild injection profile or a standardized AOD-9604 monitoring protocol.
Aod 9604 and tirzepatide together side effects are not characterized by the 2024 evaluation. Do not infer a safe or beneficial combination from a proposed metabolic mechanism.
Anyone using AOD-9604 should weigh the lack of long-term human data against any hoped-for benefit, and should consult a licensed healthcare professional before starting. Nothing here is medical advice.
Key Takeaways
- Preparation requires formulation-specific compatibility and stability evidence.
- As arithmetic only, 5 mg in a final volume of 2 mL gives 2500 mcg/mL; 300 mcg occupies 0.12 mL, or 12 U-100 units.
- That aliquot is not a recommended human dose.
- The reviewed evidence does not validate a human injection regimen.
- AOD-9604 has no FDA-approved human product and is listed under WADA S2.2.3.
Frequently Asked Questions
How much bacteriostatic water do I add to a 5 mg AOD-9604 vial?
No universal diluent volume is established. For arithmetic only, 5 mg in a final volume of 2 mL gives 2500 mcg/mL, and a hypothetical 300 mcg aliquot occupies 0.12 mL or 12 U-100 units. That does not validate the solvent, solubility, or a human dose.
What is a typical AOD-9604 dosage?
No validated human subcutaneous starting amount, daily total, or split schedule follows from the reviewed evidence. Repeated community ranges are not a clinical regimen.
How long is reconstituted AOD-9604 good for?
Use stability and beyond-use information supported for the specific form, formulation, concentration, and container. A generic two-to-four-week refrigerator rule or blanket freezing rule is not established for every mixed vial.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.